Collaboration Between Illumina Inc. and AstraZeneca Promises Groundbreaking Drug Target Discovery Using AI-Based Genomic Analysis Techniques
13 Sep 2023
DUBLIN, Sept. 13, 2023 /PRNewswire/ -- The "Global Next-Generation Sequencing on Drug Development Market" report has been added to
ResearchAndMarkets.com's offering.
The latest market analysis reveals a promising trajectory for the global Next-Generation Sequencing (NGS) in Drug Development market. With an expected surge from $1.3 billion in 2023 to a projected $2.9 billion by 2028.
The market is anticipated to experience a robust Compound Annual Growth Rate (CAGR) of 17.7%. This growth is propelled by the transformative potential of NGS technologies in revolutionizing genetic research and advancing drug development.
The comprehensive report explores a wide spectrum of NGS technologies, applications, industries, initiatives, patents, and key market players. It meticulously delineates market dynamics for NGS in drug development, offering insights into the years 2020, 2021, 2022, 2023, and the promising horizon of 2028.
NGS, founded on the concept of massive parallel sequencing that yields a plethora of relatively small reads, has emerged as an indispensable tool in genetic research. This technology has bridged critical gaps in research tools, empowering researchers to tackle complex genomic questions across diverse fields, such as de-novo genome sequencing, comparative genomics, gene expression, and gene regulation studies. As a linchpin in these research endeavors, NGS drives discoveries and lays the foundation for the future of personalized medicine.
NGS in drug discovery and development centers on two key facets: target identification and genetically stratified clinical trials. By leveraging the wealth of human genetic information, NGS facilitates the identification of drug targets, validation of therapeutic hypotheses, and prediction of safety profiles for inhibitory compounds targeting molecular markers. Its potential to uncover mutations linked to genetic diseases and identify target genes for future drug development is groundbreaking.
The adoption of NGS technologies is poised to unravel the genetic basis of human diseases, discover novel compounds, optimize drug efficacy, mitigate adverse reactions, and pave the way for personalized therapies. Notably, the pharmaceutical industry is actively engaged in population-scale NGS analyses to unearth new insights into human diseases. Additionally, focused NGS analyses in clinical trials are aimed at pinpointing biomarkers indicative of drug efficacy and safety. In the foreseeable future, NGS may usher in a wave of new compounds for the market, while genetically stratified clinical trials could be tailored to specific participant subsets based on genetic profiles and clinical biomarkers.
The report segments the global NGS market in drug development based on product type, end user, and geography, encompassing instruments, consumables, and services. Leading pharmaceutical and biotechnology companies are at the forefront of launching innovative NGS instruments tailored for drug development.
A notable example is the strategic research collaboration initiated in October 2022 between Illumina Inc. and AstraZeneca, a renowned global biopharmaceutical company. This collaboration leverages artificial intelligence (AI)-based genome interpretation and genomic analysis techniques, along with industry expertise, to accelerate drug target discovery. The integrated framework of these technologies holds the potential to enhance the efficiency and confidence in target discovery, giving rise to promising drugs rooted in human omics insights.
Companies Mentioned
Integrated Dna Technologies Inc.
Micronoma
New England Biolabs
Precision for Medicine, Formerly Apocell
Report Highlights:
52 data tables and 39 additional tables
In-depth analysis spanning the years 2020-2022, with estimates for 2023 and projections of Compound Annual Growth Rates (CAGRs) through 2028
Insights into market potential, product and service characterization, end-user segmentation, and regional trends
Exploration of key market drivers and constraints, with an emphasis on upcoming opportunities and areas of focus
Coverage of recent advancements, emerging technologies, and industry developments
Key Topics Covered:
Chapter 1 Introduction
Chapter 2 Summary and Highlights
Chapter 3 Market Overview
Chapter 4 Market Dynamics
Market Drivers
Increasing R&D Activities Using Ngs Technologies
Increase in Healthcare Expenditure
Technological Advancements in Sequencing Platforms
Shift Towards Precision Medicine
Growing Demand of Ngs for Designing Individualized Medicine to Cancer Patients
High Accuracy and Low Cost
Market Restraints
Limitations Associated With Ngs Technology
Other Clinical Sequencing Technology Challenges
Market Opportunities
Rising R&D in Ngs Creates Lucrative Opportunities for Manufacturers
Chapter 5 Ngs in Drug Development by Product Type
Introduction
Instruments
Consumables
Services
Chapter 6 Ngs Market in Drug Development by End-user
Academic and Research Centers
Other End-users
Chapter 7 Ngs Market in Drug Development by Region
Market Overview and Discussion
North America
Asia-Pacific
Europe
Rest of the World
Chapter 8 Sustainability of Ngs in Drug Development: An Esg Perspective
Introduction to Esg
Sustainability of Ngs in Drug Development: An Esg Perspective
Key Esg Issues
Consumer Attitudes Towards Esg
Industry Esg Performance Analysis
Case Study
Environment
Social
Governance
Concluding Remarks
Chapter 9 Emerging Technologies and Developments
Overview
Emerging Technologies in the Market
Application of Artificial Intelligence (Ai) in Ngs
Single-Molecule Real-Time Sequencing
Microscopy-Based Sequencing
Chapter 10 Patent Analysis
Introduction
Patents on Ngs by Region
Chapter 11 M&A and Funding Outlook
M&A Analysis
Chapter 12 Competitive Landscape
Global Company Ranking
Global Company Ranking for Ngs Instruments in Drug Development
Global Company Ranking for Ngs Consumables in Drug Development
Global Company Ranking for Ngs Services in Drug Development
Chapter 13 Company Profiles
Chapter 14 Appendix: Acronyms
For more information about this report visit https://www.researchandmarkets.com/r/psghsg
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.